for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pieris Pharmaceuticals Inc

PIRS.OQ

Latest Trade

2.71USD

Change

0.00(0.00%)

Volume

85,234

Today's Range

2.59

 - 

2.75

52 Week Range

1.60

 - 

5.96

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.71
Open
2.59
Volume
85,234
3M AVG Volume
8.81
Today's High
2.75
Today's Low
2.59
52 Week High
5.96
52 Week Low
1.60
Shares Out (MIL)
52.32
Market Cap (MIL)
134.46
Forward P/E
-4.12
Dividend (Yield %)
--

Next Event

Pieris Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343

Pieris Pharmaceuticals Files For Offering Of Up To 18.03 Million Shares Of Common Stock By Selling Stockholders

Pieris Pharmaceuticals Inc - On November 2, Entered Into A Securities Purchase Agreement For A Private Placement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Industry

Biotechnology & Drugs

Contact Info

255 State St Fl 9

BOSTON, MA

02109-2615

United States

+1.857.2468998

https://www.pieris.com/

Executive Leadership

james A. Geraghty

Independent Chairman of the Board

Stephen S. Yoder

President, Chief Executive Officer, Director

Thomas Bures

Chief Financial Officer, Principal Accounting Officer, Vice President - Finance, Treasurer

Hitto Kaufmann

Senior Vice President, Chief Scientific Officer

Ahmed Mousa

Senior Vice President - Corporate Operations , General Counsel, Secretary

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.400

2018

-0.500

2019

-0.560

2020(E)

-0.624
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.64
Price To Book (MRQ)
2.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-19.38
Return on Equity (TTM)
-14.69

Latest News

Latest News

BRIEF-Pieris Pharmaceuticals Reports Q1 Loss Per Share $0.17

* PIERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Pieris Pharmaceuticals Prices Public Offering Of 5.50 Mln Common Shares At $8/Share

* PIERIS PHARMACEUTICALS ANNOUNCES PRICING OF ITS PUBLIC OFFERING

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

BRIEF-Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060

* PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING Source text: (http://bit.ly/2oXTLTa) Further company coverage:

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402

BRIEF-Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors

* Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors

BRIEF-Pieris Pharmaceuticals reports Q3 loss per share $0.16

* Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update

BRIEF-Pieris Pharmaceuticals names Allan Reine CFO

* Pieris Pharmaceuticals appoints Allan Reine, M.D., as chief financial officer Source text for Eikon: Further company coverage:

BRIEF-Sichuan Kelun Pharmaceutical unit signs license agreement with Pieris Pharmaceuticals

* Says its Sichuan-based unit signs license agreement with Pieris Pharmaceuticals Inc, regarding a patent of tumour immunotherapy

BRIEF-Pieris Pharmaceuticals Q2 loss per share $0.23

* Pieris Pharmaceuticals reports financial results for the second quarter ended June 30, 2017 and provides corporate update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up